Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail shows promise for Hard-to-Treat myeloma

NCT ID NCT03590652

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times

Summary

This study tested a combination of four drugs (daratumumab, ixazomib, pomalidomide, and dexamethasone) in 23 people with multiple myeloma that had come back or stopped responding to earlier treatments. The goal was to see how many patients responded to the therapy. The trial was terminated early, but results may still help guide future treatment options for this blood cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • UCSD Moores Cancer Center

    La Jolla, California, 92093, United States

  • University of California, Davis

    Sacramento, California, 95817, United States

  • University of California, Los Angeles

    Los Angeles, California, 90024, United States

  • University of California, San Francisco

    San Francisco, California, 94115, United States

Conditions

Explore the condition pages connected to this study.